GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Other Stockholders Equity

Shortwave Life Sciences (AQSE:PSY) Other Stockholders Equity : £0.00 Mil (As of . 20)


View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Other Stockholders Equity?

Shortwave Life Sciences's Other Stockholders Equity for the quarter that ended in . 20 was £0.00 Mil.


Shortwave Life Sciences Other Stockholders Equity Historical Data

The historical data trend for Shortwave Life Sciences's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Other Stockholders Equity Chart

Shortwave Life Sciences Annual Data
Trend
Other Stockholders Equity

Shortwave Life Sciences Semi-Annual Data
Other Stockholders Equity

Shortwave Life Sciences Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Shortwave Life Sciences Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Shortwave Life Sciences's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shortwave Life Sciences Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.

Shortwave Life Sciences Headlines